ReviewPharmaceutics2025
Engineered Phage-Guided Nanotherapeutic Systems for Precision Antibacterial Therapy: Hacking Bacterial Resistance Mechanisms.
Review in Pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- NIR-Assisted Multimodal Strategies for Enhanced Antibacterial Therapy.Small (Weinheim an der Bergstrasse, Germany) · 2026Review
- A critical review on antibacterial mechanisms of carbon dots: a comprehensive approach to combating multidrug resistance.Archives of microbiology · 2026Review
- Engineered Phage Modulates Quorum Sensing and Biofilm Formation inMicroorganisms · 2026Article
- Liposome-Based Drug Delivery Systems: Mechanisms, Preparation Strategies, Clinical Status, and Therapeutic Applications.AAPS PharmSciTech · 2026Review
- Development and In Vivo Evaluation of QbD-Assisted Squalene-based Luliconazole Entrapped Ethosomal Gel for the Skin Fungal Infection.AAPS PharmSciTech · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Antibiotic resistance (ABR) poses a critical global public health challenge necessitating immediate action. Without prompt interventions, infections caused by antibiotic-resistant bacteria could surpass the annual mortality rates of all cancers combined by 2050. Phages are one of the most abundant biological entities on earth that specifically infect and replicate in bacterial cells and can act as potential alternatives to antibiotics. Nanotechnology provides a favorable solution to overcome various challenges linked with phage therapy. Developments in nanotechnology, including nano-encapsulation, offer solutions to various clinical as well as pharmacological challenges by improving delivery efficacy, ensuring controlled release, and protecting phages from environmental degradation and immune clearance. The synergistic actions of phage-guided targeting and the strong bactericidal potential of engineered nanocapsules (NCs) could effectively eradicate multidrug-resistant (MDR) bacteria while diminishing off-target activities. Potential applications of engineered phage-guided nanotherapeutic systems have already been explored in terms of phage/nanocarrier cocktails, enhanced antibacterial activity, effective treatment of nosocomial infections, wound healing, and disruption of bacterial biofilms. The present review focuses on comprehensively discussing the advances in phage-guided NCs along with their mechanisms in enhancing precision antibacterial therapy. In this regard, numerous in vitro and in vivo study findings have been summarized in this review. Moreover, various approaches to overcome and optimize the pharmacokinetic profiles of phage-guided NCs have been discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.